ReviewInternational journal of general medicine2025
The Role of Deregulated MicroRNAs in Immune Cells of Sjögren's Disease.
Review in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Downregulation of miRNAs Accompanies Increased HERV-K (HML-2) Expression in Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2026Article
- MicroRNA bioinformatics in precision oncology: an integrated pipeline from NGS to AI-based target discovery.Journal of applied genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2024 Nobel Prize in Physiology or Medicine, awarded for the discovery of microRNAs (miRNAs) as essential regulators of gene expression, has spotlighted their pivotal roles in disease processes, including autoimmune conditions such as Sjögren's disease (SD). SD is a chronic autoimmune disease marked by lymphocytic infiltration of exocrine glands, resulting in significant glandular dysfunction and diverse systemic effects. Recent research has revealed that miRNAs play crucial roles in SD pathogenesis, orchestrating immune cell activity, epithelial cell integrity, and the regulation of inflammatory pathways. Dysregulation of specific miRNAs is associated with exacerbated immune responses, glandular damage, epithelial cell dysfunction, and sustained inflammation, positioning these small RNA molecules as central players in disease progression. This review synthesizes current findings on the roles of miRNAs in SD, highlighting how certain miRNAs contribute to immune dysregulation, epithelial dysfunction, and disease chronicity. Additionally, we explore the potential of miRNAs as biomarkers for disease activity, reflecting both immune and epithelial health, and as novel therapeutic targets. By consolidating recent advancements, we aim to offer a comprehensive perspective on the involvement of miRNAs in SD and to underscore the potential for miRNA-based strategies to transform the diagnosis, management, and treatment of SD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.